Ramsay Générale de Santé SA operates hospitals in France.
Overvalued with weak fundamentals.
Share Price & News
How has Ramsay Générale de Santé's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GDS has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GDS matched the French Healthcare industry which returned -0.4% over the past year.
Return vs Market: GDS exceeded the French Market which returned -3.8% over the past year.
Price Volatility Vs. Market
How volatile is Ramsay Générale de Santé's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StEstimating The Fair Value Of Ramsay Générale de Santé SA (EPA:GDS)
1 month ago | Simply Wall StIs Ramsay Générale de Santé (EPA:GDS) Using Too Much Debt?
1 month ago | Simply Wall StAre Ramsay Générale de Santé's (EPA:GDS) Statutory Earnings A Good Guide To Its Underlying Profitability?
Is Ramsay Générale de Santé undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GDS (€17.35) is trading above our estimate of fair value (€15.28)
Significantly Below Fair Value: GDS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GDS is poor value based on its PE Ratio (215.3x) compared to the Healthcare industry average (29x).
PE vs Market: GDS is poor value based on its PE Ratio (215.3x) compared to the French market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GDS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GDS is good value based on its PB Ratio (1.9x) compared to the FR Healthcare industry average (2.2x).
How is Ramsay Générale de Santé forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ramsay Générale de Santé has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of GDS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Ramsay Générale de Santé competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Ramsay Générale de Santé performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GDS has a large one-off loss of €34.4M impacting its December 31 2019 financial results.
Growing Profit Margin: GDS's current net profit margins (0.2%) are lower than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: GDS's earnings have declined by -13.6% per year over the past 5 years.
Accelerating Growth: GDS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GDS had negative earnings growth (-72.1%) over the past year, making it difficult to compare to the Healthcare industry average (-6.9%).
Return on Equity
High ROE: GDS's Return on Equity (1.5%) is considered low.
How is Ramsay Générale de Santé's financial position?
Financial Position Analysis
Short Term Liabilities: GDS's short term assets (€1.0B) do not cover its short term liabilities (€1.1B).
Long Term Liabilities: GDS's short term assets (€1.0B) do not cover its long term liabilities (€4.1B).
Debt to Equity History and Analysis
Debt Level: GDS's debt to equity ratio (351.6%) is considered high.
Reducing Debt: GDS's debt to equity ratio has increased from 224.5% to 351.6% over the past 5 years.
Debt Coverage: GDS's debt is not well covered by operating cash flow (8.6%).
Interest Coverage: GDS's interest payments on its debt are not well covered by EBIT (1.9x coverage).
What is Ramsay Générale de Santé's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GDS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GDS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GDS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GDS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: GDS is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GDS's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Pascal Roché (57yo)
Mr. Pascal Roché is Chairman of the Board and Chief Executive Officer at Capio AB (publ) since December 4, 2018. Mr. Roché has been the Chief Executive Officer at Ramsay Générale de Santé SA since June 30, ...
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD0.00) is below average for companies of similar size in the French market ($USD1.16M).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
|Chairman||no data||€45.00k||no data|
|Deputy Chairman||5.67yrs||€55.00k||no data|
|Independent Director||6.25yrs||€55.00k||no data|
|Director||4.17yrs||no data||no data|
|Independent Director||6.25yrs||€45.00k||no data|
|Director||0.75yr||no data||no data|
|Director||1.67yrs||no data||no data|
Experienced Board: GDS's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ramsay Générale de Santé SA's company bio, employee growth, exchange listings and data sources
- Name: Ramsay Générale de Santé SA
- Ticker: GDS
- Exchange: ENXTPA
- Founded: 1987
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €1.915b
- Shares outstanding: 110.36m
- Website: https://www.ramsaygds.fr
Number of Employees
- Ramsay Générale de Santé SA
- 39 rue Mstislav Rostropovitch
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GDS||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Jun 2001|
|GD6||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2001|
|0OD6||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jun 2001|
|GDSP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jun 2001|
Ramsay Générale de Santé SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as heart, hand, digestive, thoracic, vascular, and endovascular surgeries. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. Ramsay Générale de Santé SA was founded in 1987 and is based in Paris, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 21:23|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.